ArticleCells2022
590 nm LED Irradiation Improved Erythema through Inhibiting Angiogenesis of Human Microvascular Endothelial Cells and Ameliorated Pigmentation in Melasma.
Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 27 citations in OpenAlex.
- Efficacy and safety of 570/590 Nm yellow light combined with red light and infrared LED in treating facial skin photoaging: A Single-Center, randomized Controlled, exploratory study.Lasers in medical science · 2025Trial
- Amber LED photobiomodulation versus tranexamic acid for the treatment of melasma: randomized controlled double-blind pilot trial.Lasers in medical science · 2025Trial
- Review
- Review
- Efficacy of Intense Pulsed Light AOPT-LTL Technique in the Treatment of Melasma: An In Vivo and Clinical Study.Journal of cosmetic dermatology · 2025Article
- Oral tranexamic acid, low-fluence intense pulsed light, and glycolic acid for the treatment of mixed melasma: An observational study.Medicine · 2025Observational
- Could photobiomodulation be used for treatment of rosacea?Lasers in medical science · 2025Review
- An Update on New and Existing Treatments for the Management of Melasma.American journal of clinical dermatology · 2024Review
- Ozonated Hydrotherapy Combined with LED Yellow Light Irradiation and Oral Minocycline Treatment for Mild to Moderate Papulopustular Rosacea: A Comparative Retrospective Study.Clinical, cosmetic and investigational dermatology · 2024Article
- The Emerging Role of Visible Light in Melanocyte Biology and Skin Pigmentary Disorders: Friend or Foe?Journal of clinical medicine · 2023Review
- Amber photobiomodulation versus tranexamic acid for the treatment of melasma: protocol for a double-blind, randomised controlled trial.BMJ open · 2023Article
- Photobiomodulation for Skin Pigmentation Disorders: A Dual-Function Treatment.Photobiomodulation, photomedicine, and laser surgery · 2023Article
- Expression of Endothelin-1, Endothelin Receptor-A, and Endothelin Receptor-B in facial melasma compared to adjacent skin.Clinical, cosmetic and investigational dermatology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melasma is a common refractory acquired pigmentary skin disease that mainly affects middle-aged women. The pathogenesis of melasma is still uncertain, while abnormal vascular endothelial cells may play a role. We previously demonstrated the yellow light of light-emitting diodes (LED) could inhibit melanogenesis through the photobiomodulation (PBM) of melanocytes and keratinocytes. In the current study, we investigated the effect of 590 nm LED on the function of human microvascular endothelial cells (HMEC-1). We revealed 0-40 J/cm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.